Modulation of eNOS activity and therapeutic uses thereof

Details Modulation of eNOS activity and therapeutic uses thereof Modulation of eNOS activity and therapeutic uses thereof

2006-07-18

2006-07-18

Allen, Marianne P. (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C530S399000

Reexamination Certificate

active

07078382

ABSTRACT:
The present invention provides uses of VEGF or VEGF receptor agonists for the up-regulation of eNOS expression and activity. VEGF and VEGF receptor agonists are useful in the treatment of or prevention from hypertension, diabetes, angina, thrombosis, atherosclerosis, heart failure, and other conditions or disorders wherein nitric oxide is an important regulator.

REFERENCES:
patent: 3773919 (1973-11-01), Boswell
patent: 3887699 (1975-06-01), Yolles
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5851999 (1998-12-01), Ullrich et al.
patent: 5955311 (1999-09-01), Rockwell et al.
patent: 6020473 (2000-02-01), Keyt et al.
patent: 6057428 (2000-05-01), Keyt et al.
patent: 6239172 (2001-05-01), Kaesemeyer
patent: 6352975 (2002-03-01), Schreiner et al.
patent: 6395707 (2002-05-01), Zioncheck et al.
patent: 6475796 (2002-11-01), Pollitt et al.
patent: 6485942 (2002-11-01), Zioncheck et al.
patent: 1176565 (1984-10-01), None
patent: 36776 (1981-09-01), None
patent: 058481 (1982-08-01), None
patent: 75444 (1983-03-01), None
patent: 158277 (1985-10-01), None
patent: WO 98/20027 (1998-05-01), None
patent: WO 90/13649 (1990-11-01), None
patent: WO 97/08313 (1997-03-01), None
patent: WO 98/16551 (1998-04-01), None
patent: WO 98/20027 (1998-05-01), None
patent: WO 00/13702 (2000-03-01), None
patent: WO 00/63380 (2000-10-01), None
patent: WO 00/71713 (2000-11-01), None
Pagliaro (2003), Life Sci 73(17): 2137-2149.
Marin et al. (1997), Pharmacol Ther 75(2): 111-134.
Gerber et al. (1998), J. Biol. Chem. 273(46): 30336-30343.
El-Mahmoudy et al. (2005), Int. Immunopharm. 5: 195-207.
Kroll et al. (1998), Biochem. Biophys. Res. Comm. 252: 743-746.
Van Belle et al. (1997), Biochem. Biophys. Res. Comm. 235: 311-316.
Losordo et al. (1998), Circulation, 98: 2800-2804.
Rosengart et al. (1999), Circulation 100: 468-474.
Isner et al. (1999), Nat. Med. 5(5): 491-492.
Bolivar et al., Gene, 2:95-113 (1977) Construction and Characterization of New Cloning Vehicles.
Cohen, Proc. Natl. Acad. Sci., (USA), 69:8, 2110-2114 (1972) Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation ofEscherichia coliby R-Factor DNA.
Fiers et al., Nature, 273:113-120 (1978) Complete Nucleotide Sequence of SV40 DNA.
Goeddel et al., Nature, 281:544-548 (1979) Direct Expression inEscherichia coliof a NDA Sequence Coding for Human Growth Hormone.
Goeddel et al., Nucleic Acids Res., 8:18, pp. 4057-4074 (1980) Synthesis of Human Fibroblast Interferon byE coli.
Graham and van der Eb, Virology, 52:456-467 (1978) A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA.
Hitzeman et al., J. Biol. Chem., 255:24, pp. 2073-12080 (1980) Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique.
Hess et al., J. Adv. Enzyme Reg., 7:149-167 (1968) Cooperation of Glycolytic Enzymes.
Holland et al., Biochemistry, 17:23, pp. 4900-4907 (1978) Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceralydehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase.
Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76:8, pp. 3829-3833 (1979) High-frequency Transformation of Yeast by Plasmids Containing the Clined Yeat ARG4Gene.
Ishikawa et al., Nature, 338:557 (1989) Identification of Angiogenic Activity and the Cloning and Expression of Platelet-derived Endotheilial Cell Growth Factor.
Itakura et al., Science, 198:1056-1063 (1977) Expression isEscherichia coliof a Chemically Synthesized Gene for the Hormone Somatostatin.
Jones, Genetics, 85:23-33 (1977) Proteinase Mutants ofSaccharomyces cerevisiae.
Keyt et al., J. Biol. Chem., 271:10, pp. 5638-5646 (1996) Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors.
Kingsman et al., Gene 7:141-152 (1979) Replication inSaccharomyces cerevisiaseof Plasmid pBR313 Carrying DNA from the Yeast trpl Region.
Kunkel et al., Meth. Enzym. 204:125-139 (1991) Efficient Site-Directed Mutagenesis Using Uracil-Containing DNA.
Laboratory Investigation, 72:615 (1995) Vascular Endothelial Growth Factor.
Oates, Chapter 33, Goodman and Gilman, 9th Edition, pp. 780-781. Antihypertensive Agents and the Drug Therapy of Hypertension.
Mandel et al., J. Mol. Biol., 53:159-162 (1970) Calcium-dependent Bacteriophase DNA Infection.
Maxam et al., Methods of Enzymology, 65:499 (1977) Sequencing End-Labeled DNA with Base-Specific Chemical Cleavages.
Messing et al., Nucleic Acids res., 9:2, pp. 309-321 (1981) A System for Shotgun DNA Sequencing.
Siebenlist et al., Cell, 20:269-281 (1980)E. coliRNA Polymerase Interacts Homologously with Two Different Promoters.
Stinchcomb et al., Nature, 282:39-43 (1979) Isolation and Characterisationof a Yeast Chromosomal Replicator.
Tschumper et al., Gene, 10:157-166 (1980) Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene.
Urlaub and Chasin, Proc. Natl. Acad. Sci. (USA), 77:4, pp. 4216-4220 (1980) Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity.
VAn Solingen et al., J. Bact., 130:946-947 (1977) Fusion of Yeast Spheroplasts.
Boerner et al., “Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes”The Journal of Immunology147(1):86-95 (1991).
Burgess and Maciag, “The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins”Annu. Rev. Biochem.58:575-606 (1989).
Busse and Fleming., “Endothelial Dysfunction in Atherosclerosis.”J. Vasc. Res.33:181-194 (1996).
Cao, Yihai et al., “Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor.”J. Bio. Chem.271:3154-3162 (1996).
De Vries et al., “The fms-Like Tyrosine Kinase, A Receptor for Vascular Endothelial Growth Factor.”Science.255:989-991 (Feb. 1992).
Drumond and Harrison., “eNOS-Overexpressing Mice: Too Much NO Makes the Blood Pressure Low.”J. Clin. Invest.102:2033-2034 (Dec. 1998).
Ferrara and Davis-Smyth., “The Biology of Vascular Endothelial Growth Factor.”Endocrine Reviews.18(1):4-25 (1997).
Ferrara and Henzel, “Pituitary Follicular Cells Secrete a Novel Heparin-binding Growth Factor Specific for Vascular Endothelial Cells”Biochem.&Biophys. Res. Comm.161(2):851-858 (1989).
Fishwild et al., “High-Avidity Human IgGκ Monoclonal Antibodies From a Novel Strain of Minilocus Transgenic Mice”Nature Biotechnology.14(7):845-851 (Jul. 1996).
Folkman., “Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease.”Nature Medicine.1(1):27-31 (1995).
Fuh et al., “Reguirements for Binding and Signaling of the Kinase Domain Receptor for Vascular Endothelial Growth Factor.”J. Bio. Chem.273(18):11197-11204 (May 1, 1998).
Hariawala et al., “VEGF Improves Myocardial Blood Flow but Produces EDRF-Mediated Hypotension in Porcine Hearts.”J. Surg. Res.63:77-82 (1996).
Hood et al., “VEGF Upregulates ecNOS Message, Protein, and NO Production in Human Endothelial Cells.”Am. J. Phys.274:H1054-H1058 (1998).
Hoogenboom and Winter, “By-Passing Immunisation: Human Antibodies from Synthetic Repertoires of Germline VHGene Segments Rearranged in Vitro”J. Mol. Biol.227:381-388 (1992).
Houck et al., “The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA.”Mol. Endocrinol.5:1806-1814 (1991).
Ishikawa et al., “Identification of Angiogenic Activity and the Cloning and Expression of Platelet-Derived Endothelial Cell Growth Factor.”Nature.338:557-562 (1989).
Jin et al., “Novel Analog of Atrial Natriuretic Peptide Selective for Receptor-A Produces Increased Diuresis and Natriuresis in Rats.”J. Cli

Affiliated with

Also associated with

Rating

Modulation of eNOS activity and therapeutic uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modulation of eNOS activity and therapeutic uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of eNOS activity and therapeutic uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3597667